Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SRXH vs HIMS vs TDOC vs OPRX vs AMWL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SRXH
SRx Health Solutions Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1M
5Y Perf.-94.2%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.-22.5%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-3.2%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-27.3%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$129M
5Y Perf.+5.7%

SRXH vs HIMS vs TDOC vs OPRX vs AMWL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SRXH logoSRXH
HIMS logoHIMS
TDOC logoTDOC
OPRX logoOPRX
AMWL logoAMWL
IndustryDrug Manufacturers - GeneralMedical - Equipment & ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$1M$6.63B$1.26B$124M$129M
Revenue (TTM)$119M$2.35B$2.51B$109M$182M
Net Income (TTM)$-11M$128M$-171M$5M$-88M
Gross Margin19.9%69.7%65.6%67.3%38.7%
Operating Margin-4.9%4.6%-7.6%10.7%-50.6%
Forward P/E51.5x7.0x
Total Debt$39M$1.12B$1.04B$5M$5M
Cash & Equiv.$2M$229M$781M$23M$182M

SRXH vs HIMS vs TDOC vs OPRX vs AMWLLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SRXH
HIMS
TDOC
OPRX
AMWL
StockApr 25May 26Return
SRx Health Solution… (SRXH)1005.8-94.2%
Hims & Hers Health,… (HIMS)10077.5-22.5%
Teladoc Health, Inc. (TDOC)10096.8-3.2%
OptimizeRx Corporat… (OPRX)10072.7-27.3%
American Well Corpo… (AMWL)100105.7+5.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: SRXH vs HIMS vs TDOC vs OPRX vs AMWL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HIMS leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. American Well Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. OPRX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Lower-Volatility Pick

SRXH lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 161.9% 10Y total return vs OPRX's 110.5%
  • 59.0% revenue growth vs AMWL's -2.0%
  • 5.5% margin vs AMWL's -48.2%
Best for: growth exposure and long-term compounding
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
OPRX
OptimizeRx Corporation
The Value Play

OPRX ranks third and is worth considering specifically for value.

  • Better valuation composite
Best for: value
AMWL
American Well Corporation
The Income Pick

AMWL is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • beta 1.47
  • Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
  • Beta 1.47, current ratio 3.37x
  • Beta 1.47 vs HIMS's 2.40, lower leverage
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs AMWL's -2.0%
ValueOPRX logoOPRXBetter valuation composite
Quality / MarginsHIMS logoHIMS5.5% margin vs AMWL's -48.2%
Stability / SafetyAMWL logoAMWLBeta 1.47 vs HIMS's 2.40, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)AMWL logoAMWL+14.3% vs SRXH's -84.6%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs AMWL's -25.1%, ROIC 10.7% vs -95.1%

SRXH vs HIMS vs TDOC vs OPRX vs AMWL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SRXHSRx Health Solutions Inc.

Segment breakdown not available.

HIMSHims & Hers Health, Inc.

Segment breakdown not available.

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
OPRXOptimizeRx Corporation

Segment breakdown not available.

AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M

SRXH vs HIMS vs TDOC vs OPRX vs AMWL — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHIMSLAGGINGAMWL

Income & Cash Flow (Last 12 Months)

HIMS leads this category, winning 3 of 6 comparable metrics.

TDOC is the larger business by revenue, generating $2.5B annually — 23.0x OPRX's $109M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
RevenueTrailing 12 months$119M$2.3B$2.5B$109M$182M
EBITDAEarnings before interest/tax$164M$42M$16M-$59M
Net IncomeAfter-tax profit$128M-$171M$5M-$88M
Free Cash FlowCash after capex$73M$251M$12M-$42M
Gross MarginGross profit ÷ Revenue+19.9%+69.7%+65.6%+67.3%+38.7%
Operating MarginEBIT ÷ Revenue-4.9%+4.6%-7.6%+10.7%-50.6%
Net MarginNet income ÷ Revenue-9.4%+5.5%-6.8%+4.7%-48.2%
FCF MarginFCF ÷ Revenue+1.3%+3.1%+10.0%+10.6%-22.9%
Rev. Growth (YoY)Latest quarter vs prior year+28.4%-2.5%-0.2%-100.0%
EPS Growth (YoY)Latest quarter vs prior year-27.3%+32.1%+44.5%
HIMS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SRXH and OPRX each lead in 2 of 6 comparable metrics.

At 24.6x trailing earnings, OPRX trades at a 51% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than HIMS's 42.7x.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Market CapShares × price$1M$6.6B$1.3B$124M$129M
Enterprise ValueMkt cap + debt − cash$29M$7.5B$1.5B$105M-$48M
Trailing P/EPrice ÷ TTM EPS-0.17x50.32x-6.11x24.56x-1.30x
Forward P/EPrice ÷ next-FY EPS est.51.51x7.04x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple42.68x15.13x6.55x
Price / SalesMarket cap ÷ Revenue0.02x2.82x0.50x1.13x0.52x
Price / BookPrice ÷ Book value/share12.25x0.89x0.98x0.50x
Price / FCFMarket cap ÷ FCF1.20x89.61x4.40x6.62x
Evenly matched — SRXH and OPRX each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs SRXH's 3/9, reflecting strong financial health.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
ROE (TTM)Return on equity+23.7%-12.4%+4.2%-33.5%
ROA (TTM)Return on assets-22.4%+6.0%-5.9%+3.0%-25.1%
ROICReturn on invested capital-18.1%+10.7%-11.5%+7.1%-95.1%
ROCEReturn on capital employed-98.8%+10.9%-10.0%+7.6%-36.6%
Piotroski ScoreFundamental quality 0–934686
Debt / EquityFinancial leverage2.07x0.75x0.04x0.02x
Net DebtTotal debt minus cash$37M$892M$259M-$19M-$178M
Cash & Equiv.Liquid assets$2M$229M$781M$23M$182M
Total DebtShort + long-term debt$39M$1.1B$1.0B$5M$5M
Interest CoverageEBIT ÷ Interest expense-2.83x-8.76x1.26x-239.18x
HIMS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs SRXH's -62.3% — a key indicator of consistent wealth creation.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
YTD ReturnYear-to-date-52.9%-23.2%-1.3%-46.6%+59.8%
1-Year ReturnPast 12 months-84.6%-51.0%+1.5%-30.1%+14.3%
3-Year ReturnCumulative with dividends-94.6%+116.6%-73.3%-54.4%-80.7%
5-Year ReturnCumulative with dividends-94.6%+137.6%-95.4%-87.3%-97.2%
10-Year ReturnCumulative with dividends-94.6%+161.9%-41.1%+110.5%-98.3%
CAGR (3Y)Annualised 3-year return-62.3%+29.4%-35.6%-23.0%-42.2%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SRXH and AMWL each lead in 1 of 2 comparable metrics.

SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Beta (5Y)Sensitivity to S&P 500-0.32x2.40x1.91x2.28x1.47x
52-Week HighHighest price in past year$1.25$70.43$9.77$22.25$9.15
52-Week LowLowest price in past year$0.08$13.74$4.40$5.54$3.71
% of 52W HighCurrent price vs 52-week peak+9.0%+36.4%+71.2%+29.8%+84.7%
RSI (14)Momentum oscillator 0–10041.454.574.146.967.1
Avg Volume (50D)Average daily shares traded22.0M34.9M5.5M476K59K
Evenly matched — SRXH and AMWL each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: HIMS as "Hold", TDOC as "Hold", OPRX as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 8.9% for TDOC (target: $8).

MetricSRXH logoSRXHSRx Health Soluti…HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Analyst RatingConsensus buy/hold/sellHoldHoldBuy
Price TargetConsensus 12-month target$29.67$7.58$17.00
# AnalystsCovering analysts194215
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.4%0.0%0.0%+0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

HIMS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallHims & Hers Health, Inc. (HIMS)Leads 3 of 6 categories
Loading custom metrics...

SRXH vs HIMS vs TDOC vs OPRX vs AMWL: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SRXH or HIMS or TDOC or OPRX or AMWL a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SRXH or HIMS or TDOC or OPRX or AMWL?

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

6x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x.

03

Which is the better long-term investment — SRXH or HIMS or TDOC or OPRX or AMWL?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SRXH or HIMS or TDOC or OPRX or AMWL?

By beta (market sensitivity over 5 years), SRx Health Solutions Inc.

(SRXH) is the lower-risk stock at -0. 32β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -844% more volatile than SRXH relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SRXH or HIMS or TDOC or OPRX or AMWL?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SRXH or HIMS or TDOC or OPRX or AMWL?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -38. 4% for American Well Corporation — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SRXH or HIMS or TDOC or OPRX or AMWL more undervalued right now?

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 44. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

08

Which pays a better dividend — SRXH or HIMS or TDOC or OPRX or AMWL?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SRXH or HIMS or TDOC or OPRX or AMWL better for a retirement portfolio?

For long-horizon retirement investors, SRx Health Solutions Inc.

(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SRXH and HIMS and TDOC and OPRX and AMWL?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRXH is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; AMWL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SRXH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

OPRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 40%
Run This Screen
Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SRXH and HIMS and TDOC and OPRX and AMWL on the metrics below

Revenue Growth>
%
(SRXH: 28.4% · HIMS: 28.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.